These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 3051398)

  • 21. Cancer treatment protocols. Who gets chosen?
    Goodwin JS; Hunt WC; Humble CG; Key CR; Samet JM
    Arch Intern Med; 1988 Oct; 148(10):2258-60. PubMed ID: 3178383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of advanced urothelial cancer trials of the Eastern Cooperative Oncology Group.
    Dreicer R; Roth B; Wilding G;
    Cancer; 2003 Apr; 97(8 Suppl):2109-14. PubMed ID: 12673703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of measurement error on response rates.
    Warr D; McKinney S; Tannock I
    Cancer Treat Rep; 1985 Oct; 69(10):1127-32. PubMed ID: 4042092
    [No Abstract]   [Full Text] [Related]  

  • 24. Amsacrine (AMSA)--a clinical review.
    Louie AC; Issell BF
    J Clin Oncol; 1985 Apr; 3(4):562-92. PubMed ID: 3884748
    [No Abstract]   [Full Text] [Related]  

  • 25. SOP 02: Evaluation and selection of a clinical trial proposal for CESAR.
    Onkologie; 2003 Oct; 26 Suppl 6():5-10. PubMed ID: 23570178
    [No Abstract]   [Full Text] [Related]  

  • 26. An efficient design for phase III studies of combination chemotherapies.
    Ellenberg SS; Eisenberger MA
    Cancer Treat Rep; 1985 Oct; 69(10):1147-54. PubMed ID: 4042093
    [No Abstract]   [Full Text] [Related]  

  • 27. The marriage of growth factor inhibitors and chemotherapy: bliss or bust?
    Staal S; O'Connell MJ; Allegra CJ
    J Clin Oncol; 2009 Apr; 27(10):1545-8. PubMed ID: 19224842
    [No Abstract]   [Full Text] [Related]  

  • 28. Nanomedicine for Combination Therapy of Cancer.
    He C; Chan C; Weichselbaum RR; Fleming GF; Yamada SD; Lin W
    EBioMedicine; 2015 May; 2(5):366-7. PubMed ID: 26137577
    [No Abstract]   [Full Text] [Related]  

  • 29. [Oxaliplatin (Eloxatin). Progress in tumor therapy. 2004. Introduction].
    Schmoll HJ
    Onkologie; 2004 Aug; 27 Suppl 1():1. PubMed ID: 23570153
    [No Abstract]   [Full Text] [Related]  

  • 30. Teaming up to engage the immune system.
    Cancer Discov; 2014 May; 4(5):501. PubMed ID: 24794992
    [No Abstract]   [Full Text] [Related]  

  • 31. [Difficulties of therapeutic trials in oncology].
    De Gramont A; Debray J
    Ann Med Interne (Paris); 1987; 138(3):163-5. PubMed ID: 3619244
    [No Abstract]   [Full Text] [Related]  

  • 32. Drugs that lack single-agent activity: are they worth pursuing in combination?
    Gyawali B; Prasad V
    Nat Rev Clin Oncol; 2017 Apr; 14(4):193-194. PubMed ID: 28266519
    [No Abstract]   [Full Text] [Related]  

  • 33. FAM (5-fluorouracil, doxorubicin, and mitomycin) plus triazinate (FAM-T) in gastric carcinoma: a combined phase II trial of the Mid-Atlantic Oncology Program and the Pan American Health Organization.
    Ahlgren JD; Smith FP; Cazap E; Estevez RA; Marantz A; Woolley PV; Wilcosky T; Stein J; Schein PS
    Cancer Treat Rep; 1987 Apr; 71(4):419-20. PubMed ID: 3548959
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemotherapy for advanced urothelial cancer.
    Yagoda A
    Semin Urol; 1983 Feb; 1(1):60-74. PubMed ID: 6382528
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical investigations on chemotherapy at the Provincial Institute of Oncology in Madrid].
    Pérez Manga G
    Rev Esp Oncol; 1982; 29(4):777-83. PubMed ID: 6765423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [New antineoplastic antibiotics of the anthracycline group and the prospects of their clinical use].
    Viadro MM; Terent'eva TG
    Antibiot Khimioter; 1988 May; 33(5):370-9. PubMed ID: 3046531
    [No Abstract]   [Full Text] [Related]  

  • 37. International Clinical Trials in Radiation Oncology. The late effects of toxicity scoring.
    Rubin P; Wasserman TH
    Int J Radiat Oncol Biol Phys; 1988; 14 Suppl 1():S29-38. PubMed ID: 3292479
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibitors of farnesyltransferase: a rational approach to cancer chemotherapy?
    Bell IM
    J Med Chem; 2004 Apr; 47(8):1869-78. PubMed ID: 15055985
    [No Abstract]   [Full Text] [Related]  

  • 39. Thinking Systematically About the Off-Label Use of Cancer Drugs and Combinations for Patients Who Have Exhausted Proven Therapies.
    Mailankody S; Prasad V
    Oncologist; 2016 Sep; 21(9):1031-2. PubMed ID: 27401893
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving the chemotherapy experience.
    Oncology (Williston Park); 1999 Sep; 13(9):1202, 1207. PubMed ID: 10509316
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.